Get UpdatesFor US healthcare professionals only
Get Updates

What you may not see is that the symptom burden of systemic mastocytosis (SM), including the indolent subtype, can significantly disrupt patients’ lives1,2

Indolent systemic mastocytosis (ISM) represents ~90% of SM cases,3 and the symptoms of ISM can impact patients’ work, social lives, and overall well-being1,2

“I tend to isolate when I have more symptoms. I stay in a lot, and it can feel depressing.”

Teri, a patient describing living with ISM

Watch the video to learn from Kristine and Sarah, 2 patients living with SM, about how ISM impacts their everyday lives

Watch a video to learn from Kristine and Sarah, 2 patients living with SM, about how ISM impacts their everyday lives
  • These individuals receive compensation from Blueprint Medicines for sharing their experience living with systemic mastocytosis through the Blueprint Medicines SM Ambassador Program.

Patients with ISM reported reducing work hours and avoiding leaving their homes because of their symptoms1,2*

To help understand the daily impact of symptoms on patients living with SM, Blueprint Medicines sponsored and developed a patient survey in collaboration with SM physician experts and SM patient advocates. 37 patients with ISM were surveyed, and among the 32 patients with moderate to severe ISM, the symptoms of ISM resulted in2*:

~56%

of patients reported

reducing their work hours

28%

of patients reported going on

medical disability

72%

of patients reported

avoiding leaving
their homes

A majority of patients with ISM have also reported feelings of depression, fatigue, and forgetfulness4†

Despite taking multiple symptom-directed therapies, many patients still have significant symptom burden2*

“I’ve taken many different
medications, and found
that my symptoms just
weren’t resolved.”

Teri, a patient describing living with ISM

In the Blueprint Medicines-sponsored patient-reported survey, of patients with ISM (n=37)2*:

86% of patients reported moderate to severe symptom burden

Many patients are hesitant to speak up. In the Blueprint Medicines–sponsored patient-reported survey, among the subset of patients with ISM (n=37)5*:

38%

only discuss symptoms with their HCP
when they feel really bad

24%

feel they are burdening their HCP when
discussing how they are feeling

The Mastocytosis Control Test (MCT) helps assess
disease control - a tool that may be useful to support
conversations with your patients.6†‡

Woman distressed

Could ongoing uncontrolled disease signal a need to reassess your patients' disease management strategy?

EXPLORE A TREATMENT
OPTION FOR ISM

  • *In the Blueprint Medicines-sponsored TouchStone SM Patient Survey, 56 US adults with a self-reported SM diagnosis completed a 100-item survey. An unpublished analysis of a subset of those patients with ISM (N=37), including 32 with moderate to severe ISM symptoms (defined as an ISM-SAF TSS ≥28), was conducted.5
  • †The MCT was developed at Charité by a team led by PD Dr. Frank Siebenhaar, PD Dr. Karsten Weller and Prof. Dr. Marcus Maurer with Dr. Cem Akin as a co-author. Blueprint Medicines (BPM) has secured a commercial license for distribution of this test to US healthcare providers only. If you have any questions on how this test was developed, please refer to the publication and/or BPM Medical Information at medinfo@blueprintmedicines.com or 1-888-BLU-PRNT (1-888-258-7768).
  • ‡Instructions are for US HCPs only and not to be shared with patients.

Find answers to FAQs on SM

FAQs